The recent American Diabetes Association conference in New Orleans provided significant insights into diabetes and obesity treatments.
Among the topics discussed were advancements related to triple hormone receptors and their potential implications for obesity management.
Additionally, a new monthly obesity drug was highlighted, which may offer a novel approach to treating this widespread issue.